EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prescription stimulant consumption in the United States compared with 35 other countries

Marcus A Bachhuber, Ashly E Jordan iD, Brian J Piper iD

Health Affairs Scholar · 29.05.2026 · 4 (6)

DOI: 10.1093/haschl/qxag133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs Scholar, online erschienen am 29.05.2026. Verfasst von Marcus A Bachhuber und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Evidence-Based Policy, Oregon Health & Science University, Portland, OR 97239, United States. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Previous studies have identified the United States as a global outlier in stimulant prescribing. Given that stimulant prescribing in the United States has continued to increase, we aimed to provide current international comparisons.

Methods

We analyzed 2024 stimulant consumption data from the International Narcotics Control Board, reported as defined daily doses for statistical purposes (S-DDD) per 1000 population per day. We compared the United States with 35 Organization for Economic Cooperation and Development members.

Results

Overall, the United States comprised 26.8% of the population and consumed 67.6% of prescription stimulants. Per 1000 population per day, the United States had the second highest prescription stimulant consumption after Iceland. The volume of prescription stimulants consumed in the United States per 1000 population per day was 569% of the mean of comparison countries. Further, only 31.2% of consumed prescription stimulants in the United States was methylphenidate, vs 88.8% in comparison countries.

Conclusion

Additional research is needed on the clinical and public health consequences of these major differences in controlled substance policy and clinical practice between the United States and other countries. For example, findings suggest a need to better understand any differential addictive potential of prescription stimulant regimens.

Schlagwörter

Stichwörter der Autor:innen

ADHDamphetaminesmethylphenidatepharmaceutical policy

Autor:innen und Institutionen

  • Center for Evidence-Based Policy, Oregon Health & Science University, Portland, OR 97239, United States.
  • Department of Medicine, Oregon Health & Science University, Portland, OR 97239, United States.
  • New York State Office of Addiction Services and Supports, New York, NY 12203, United States.
  • Department of Medical Education, Geisinger College of Health Science, Scranton, PA 18509, United States.
  • Center for Pharmacy Innovation & Outcomes, Geisinger, Danville, PA 17822, United States.

ORCID-Profile: Ashly E Jordan, Brian J Piper

Zitieren

APA

Bachhuber, M. A., Jordan, A. E., & Piper, B. J. (2026). Prescription stimulant consumption in the United States compared with 35 other countries. Health Affairs Scholar, 4(6). https://doi.org/10.1093/haschl/qxag133

Vancouver

Bachhuber MA, Jordan AE, Piper BJ. Prescription stimulant consumption in the United States compared with 35 other countries. Health Affairs Scholar. 2026;4(6). doi:10.1093/haschl/qxag133

BibTeX
@article{Bachhuber2026,
  author = {Bachhuber, Marcus A and Jordan, Ashly E and Piper, Brian J},
  title = {Prescription stimulant consumption in the United States compared with 35 other countries},
  journal = {Health Affairs Scholar},
  year = {2026},
  volume = {4},
  number = {6},
  doi = {10.1093/haschl/qxag133}
}
Kostenlos starten →